Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Short Interest Update

Greenwich LifeSciences, Inc. (NASDAQ:GLSI - Get Free Report) saw a large growth in short interest in the month of April. As of April 15th, there was short interest totalling 910,700 shares, a growth of 22.5% from the March 31st total of 743,300 shares. Based on an average daily trading volume, of 69,700 shares, the short-interest ratio is presently 13.1 days. Approximately 15.3% of the company's stock are sold short.

Insider Buying and Selling at Greenwich LifeSciences

In other news, CEO Snehal Patel bought 5,500 shares of the business's stock in a transaction that occurred on Friday, April 4th. The shares were purchased at an average cost of $8.73 per share, for a total transaction of $48,015.00. Following the completion of the purchase, the chief executive officer now owns 5,558,002 shares of the company's stock, valued at approximately $48,521,357.46. This represents a 0.10 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders acquired 18,100 shares of company stock valued at $164,835 in the last 90 days. Company insiders own 51.67% of the company's stock.

Institutional Trading of Greenwich LifeSciences

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Northern Trust Corp increased its position in Greenwich LifeSciences by 17.3% during the fourth quarter. Northern Trust Corp now owns 87,423 shares of the company's stock worth $982,000 after buying an additional 12,923 shares during the period. Barclays PLC increased its holdings in shares of Greenwich LifeSciences by 323.3% in the 3rd quarter. Barclays PLC now owns 8,560 shares of the company's stock valued at $123,000 after acquiring an additional 6,538 shares during the period. Geode Capital Management LLC boosted its stake in shares of Greenwich LifeSciences by 4.6% during the third quarter. Geode Capital Management LLC now owns 133,550 shares of the company's stock worth $1,919,000 after buying an additional 5,861 shares during the period. JPMorgan Chase & Co. lifted its position in Greenwich LifeSciences by 172.0% during the 4th quarter. JPMorgan Chase & Co. now owns 7,061 shares of the company's stock worth $79,000 after acquiring an additional 4,465 shares during the period. Finally, Brown Brothers Harriman & Co. purchased a new position in Greenwich LifeSciences in the 4th quarter valued at $45,000. Institutional investors and hedge funds own 4.16% of the company's stock.

Greenwich LifeSciences Price Performance

Shares of GLSI traded up $0.01 during mid-day trading on Friday, reaching $9.99. The company's stock had a trading volume of 28,026 shares, compared to its average volume of 45,454. The company's 50 day moving average is $10.44 and its 200 day moving average is $12.13. The stock has a market cap of $132.61 million, a PE ratio of -12.49 and a beta of 1.76. Greenwich LifeSciences has a 12-month low of $8.06 and a 12-month high of $18.75.

Greenwich LifeSciences (NASDAQ:GLSI - Get Free Report) last posted its earnings results on Tuesday, April 15th. The company reported ($0.61) EPS for the quarter, missing analysts' consensus estimates of ($0.21) by ($0.40). As a group, sell-side analysts anticipate that Greenwich LifeSciences will post -0.8 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, HC Wainwright lifted their price objective on shares of Greenwich LifeSciences from $38.00 to $39.00 and gave the stock a "buy" rating in a research report on Monday, April 21st.

About Greenwich LifeSciences

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.